AD1
AD1 Holdings Limited
🇦🇺 ASX
🎥 MEDIA
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 56.92%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
AD1 Holdings Ltd. provides an on-line database and search platform to link employers and job candidates. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2016-06-23. The firm builds, manages, and acquires software businesses that develop specialized software solutions to address the specific needs of the global workforce. The firm operates in two main verticals: HR Services and Niche Services. Under HR services the Company provides talent recruitment solutions in the form of ApplyDirect and mentoring products under the Art of Mentoring banner. ApplyDirect provides customer-branded recruitment marketing platforms and related digital services. Jobtale provides a purpose-built recruitment platform that organizations can use to create appealing and informative job ads to attract top talent. Its Utility software services provides a suite of software solutions that support energy retailers to optimize their operations from billing and payments to customer relationship management and end-to-end customer portals.
📈 Performance
Price History
-75.00%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.05
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AD1
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in AD1
819 days
AD1 investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in AD1 also invest in...
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
13.83%
📊 Share price
$16.17 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
🙌 Performance (5Yr p.a)
10.50%
📊 Share price
$37.16 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
🩺 HEALTH CARE
📈 HIGH PRICE GROWTH
DHHF is an all-in-one investment solution, constructed using a passive blend of cost-effective ETFs traded on the ASX and other global exchanges. The ETF has a 100% allocation to shares, and is invested in a blend of large, mid and small cap equities from Australia, global developed and emerging markets, offering investors exposure to an ‘all-cap, all-world’ share portfolio with the potential for high growth over the long term. The ETF provides exposure to approximately 8,000 equity securities listed on over 60 global exchanges, in one ASX trade.
🙌 Performance (5Yr p.a)
9.60%
📊 Share price
$36.85 AUD
📈 HIGH PRICE GROWTH
🌏 GLOBAL
DZZF.AX was created on 2019-12-10 by BetaShares. The fund's investment portfolio concentrates primarily on target risk asset allocation. DZZF.AX aims to provide access to a cost-effective, true-to-label multi-asset ethical portfolio that offers high growth potential over the long term.
🙌 Performance (5Yr p.a)
5.10%
📊 Share price
$31.34 AUD
🌏 GLOBAL
GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.
🙌 Performance (5Yr p.a)
4.37%
📊 Share price
$32.29 AUD
💸 FINANCIALS
🏭 INDUSTRIALS
🇦🇺 AUSTRALIA
Want more shares? Try these...
AD8
Audinate Group Ltd. engages in the development and commercialization of audio visual software and hardware. The Company’s principal activity is the development and sale of digital audiovisual (AV) networking solutions. Dante is its technology platform that distributes digital audio and video signals over computer networks. Dante comprises software and chips, cards and modules that are sold to and integrated inside the AV products of its original equipment manufacturer (OEM) customers. The firm also provides a series of products and services to AV professionals, including AVIO adapters and management and control software. Its Dante IP networking solution is used extensively in the professional live sound, commercial installation, broadcast, public address, and recording industries. Dante replaces traditional analogue cables by transmitting synchronized AV signals across large distances to multiple locations at once, using nothing more than an ethernet cable.
🙌 Performance (5Yr p.a)
-1.79%
📊 Share price
$7.31 AUD
🔨 COMMERCIAL SERVICES & SUPPLIES
Adacel Technologies Ltd. develops and sells simulation and software applications and services. The company is headquartered in South Melbourne, Victoria. The firm's segments include systems and services. The systems segment includes all sales of complex systems and products covering operational control as well as simulation and training, and the hardware and software upgrade business. The services segment includes all aspects of support, field services and on-site technical services. REVAL, its flagship system, is a virtual air traffic control tower system that delivers a spectrum of digital tower operational solutions, from consulting services to system design, development, deployment and support. REVAL applications include single digital tower, multiple digital tower and contingency digital tower. Its Aurora Air Traffic Management (ATM) System integrates oceanic, approach, and tower control capabilities, which manages procedural airspace in a surveillance environment.
🙌 Performance (5Yr p.a)
-4.96%
📊 Share price
$0.46 AUD
🤖 TECHNOLOGY
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
🙌 Performance (5Yr p.a)
-4.96%
📊 Share price
$0.03 AUD
🧬 BIOTECHNOLOGY
